Quick Answer
Perspective Therapeutics, Inc. reported Diluted EPS of $1.40 per share (loss) for fiscal year 2025.
Perspective Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.40 | -13.8% |
| 2024 | -$1.23 | +29.3% |
| 2023 | -$1.74 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.35 | -66.7% | -20.7% |
| June 30, 2025 | -$0.29 | -61.1% | -16.0% |
| March 31, 2025 | -$0.25 | +0.0% | -19.0% |
| September 30, 2024 | -$0.21 | +43.2% | -16.7% |
| June 30, 2024 | -$0.18 | +55.0% | +28.0% |
| March 31, 2024 | -$0.25 | — | +32.4% |
| September 30, 2023 | -$0.37 | — | +7.5% |
| June 30, 2023 | -$0.40 | — | — |
- Perspective Therapeutics, Inc. showed a decrease of -13.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, Perspective Therapeutics, Inc.’s diluted eps has grown by 19.5% (from $1.74 per share (loss) to $1.40 per share (loss)).
- The most recent figure is from Perspective Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: